Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Fuller's reports continued strong trading

(Sharecast News) - Fuller, Smith & Turner reported like-for-like sales growth of 5.0% for the first 16 weeks of its financial year, as the pub and hotel operator continued to deliver a strong trading performance. In a statement issued ahead of its annual general meeting on Tuesday, the company said the positive momentum reflected the continued efforts of its teams across the business in navigating industry challenges.

"I am delighted with our progress so far this year," said chief executive Simon Emeny.

"Our teams across the business continue to work hard, delivering consistently excellent results and overcoming the challenges in our sector with spirit and determination to maintain our strong momentum.

"They are the heart of Fuller's, and I am proud to work alongside them."

The London-listed firm said the meeting also marked the retirement of chairman Michael Turner after 47 years with the company.

"It's been a wonderful journey, and I am so proud of everything that the team has achieved at Fuller's during my tenure," said Turner.

"The company celebrates 180 years this year and it has never been in a stronger position."

Fuller's said it would release its next trading update alongside half-year results on 12 November.

At 1100 BST, shares in Fuller, Smith & Turner were up 1.6% at 573p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.